Cardiac Valve and Other Major Cardiothoracic Procedures DRG Reimbursement

DRG 218 includes cardiac valve and other major cardiothoracic procedures performed with cardiac catheterization when there are no Complication or Comorbidity or Major Complication or Comorbidity, covering high-resource surgical and catheterization care. This Diagnosis-Related Group is important for inpatient reimbursement because its assignment drives Medicare payment levels based on the intensity of operative and catheterization services.

DRG 218 Overview

DRG 218 covers hospital admissions for cardiac valve and other major cardiothoracic procedures performed with cardiac catheterization when no Complication or Comorbidity or Major Complication or Comorbidity is present. This group captures complex operative cardiac interventions combined with catheter-based diagnostic or interventional procedures and influences inpatient payment because of the higher resource intensity associated with surgical and catheterization services. Case mix assignment to this Diagnosis-Related Group affects Medicare payment rates through relative weight determination and payment classification. Accurate coding of procedures and diagnoses is essential to ensure appropriate Medicare Severity Diagnosis-Related Group assignment.

Acute perioperative intervention trials focusing on strategies to reduce intraoperative and immediate postoperative complications during cardiac valve and major cardiothoracic procedures with concomitant cardiac catheterization. These studies enroll patients undergoing valve repair/replacement or other major cardiothoracic operations who also require diagnostic or interventional catheterization during the same hospitalization, and they test protocols such as anticoagulation timing, hemodynamic monitoring strategies, or minimally invasive hybrid approaches. Results inform surgeons and anesthesiologists about practices that can shorten OR and ICU time, lower complication rates, and reduce resource use—directly impacting hospital length of stay and payer expenditures for this high-cost DRG.
Comparative effectiveness research comparing surgical approaches, device selection, or hybrid procedural sequences in patients with complex valvular disease who undergo concurrent cardiac catheterization. These cohort studies or randomized pragmatic trials evaluate outcomes such as perioperative morbidity, need for reintervention, transfusion rates, and short-term functional recovery across different surgical techniques (for example, full sternotomy versus less invasive access or timing/order of catheterization versus surgery). Payers and providers use this evidence to determine which approaches yield better clinical outcomes and lower total episode costs for patients classified in this DRG.
Post-discharge outcomes and health services research assessing readmissions, rehabilitation needs, long-term functional status, and costs for survivors of valve and major cardiothoracic procedures with catheterization. These longitudinal studies follow patients after hospital discharge to identify predictors of 30- and 90-day readmission, durable quality-of-life, and utilization of post-acute care (skilled nursing, home health, cardiac rehab), with subgroup analyses for patients with comorbidities such as heart failure or chronic kidney disease. Findings are relevant to case managers and payers aiming to design care pathways, transitional care programs, and bundled-payment models that reduce readmissions and total cost of care for this DRG.

Acute perioperative intervention trials focusing on strategies to reduce intraoperative and immediate postoperative complications during cardiac valve and major cardiothoracic procedures with concomitant cardiac catheterization. These studies enroll patients undergoing valve repair/replacement or other major cardiothoracic operations who also require diagnostic or interventional catheterization during the same hospitalization, and they test protocols such as anticoagulation timing, hemodynamic monitoring strategies, or minimally invasive hybrid approaches. Results inform surgeons and anesthesiologists about practices that can shorten OR and ICU time, lower complication rates, and reduce resource use—directly impacting hospital length of stay and payer expenditures for this high-cost DRG.
Comparative effectiveness research comparing surgical approaches, device selection, or hybrid procedural sequences in patients with complex valvular disease who undergo concurrent cardiac catheterization. These cohort studies or randomized pragmatic trials evaluate outcomes such as perioperative morbidity, need for reintervention, transfusion rates, and short-term functional recovery across different surgical techniques (for example, full sternotomy versus less invasive access or timing/order of catheterization versus surgery). Payers and providers use this evidence to determine which approaches yield better clinical outcomes and lower total episode costs for patients classified in this DRG.
Post-discharge outcomes and health services research assessing readmissions, rehabilitation needs, long-term functional status, and costs for survivors of valve and major cardiothoracic procedures with catheterization. These longitudinal studies follow patients after hospital discharge to identify predictors of 30- and 90-day readmission, durable quality-of-life, and utilization of post-acute care (skilled nursing, home health, cardiac rehab), with subgroup analyses for patients with comorbidities such as heart failure or chronic kidney disease. Findings are relevant to case managers and payers aiming to design care pathways, transitional care programs, and bundled-payment models that reduce readmissions and total cost of care for this DRG.

OpenPayer

Summary & Overview

Cardiac Valve and Other Major Cardiothoracic Procedures with Cardiac Catheterization without CC/MCC: Inpatient Reimbursement Overview

DRG 218 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes